Literature DB >> 1384333

Elevated maternal serum alpha-fetoprotein levels and midtrimester placental abnormalities in relation to subsequent adverse pregnancy outcomes.

M A Williams1, D E Hickok, R W Zingheim, D A Luthy, J Kimelman, D A Nyberg, B S Mahony.   

Abstract

OBJECTIVE: Unexplained elevations of maternal serum alpha-fetoprotein levels in the second trimester of pregnancy are associated with adverse pregnancy outcomes, including intrauterine growth retardation, preterm delivery, preeclampsia, and abruptio placentae. In addition, elevations of maternal serum alpha-fetoprotein have been associated with placental lesions detected during second-trimester ultrasonographic evaluations. We examined the relationship between adverse pregnancy outcomes and unexplained elevations of maternal serum alpha-fetoprotein and placental abnormalities in the second trimester of pregnancy. STUDY
DESIGN: During the period from January 1989 to March 1991 we conducted a cohort study of 201 women with an elevated maternal serum alpha-fetoprotein (> or = 2.0 multiples of the median) and a second-trimester ultrasonographic evaluation at Swedish Hospital Medical Center and 211 women with normal maternal serum alpha-fetoprotein levels who had also undergone ultrasonographic evaluation at the same institution. All women in this investigation had singleton pregnancies without fetal anomalies.
RESULTS: Elevated maternal serum alpha-fetoprotein was associated with the following adverse pregnancy outcomes: low birth weight (adjusted risk ratio 3.7), preterm delivery (adjusted risk ratio 3.6), intrauterine growth retardation (adjusted risk ratio 4.0), preeclampsia (adjusted risk ratio 3.8) and abruptio placentae (adjusted risk ratio 4.8). Placental abnormalities detected during second-trimester ultrasonographic evaluations were also associated with adverse pregnancy outcomes: low birth weight (adjusted risk ratio 2.0), preterm delivery (adjusted risk ratio 2.3), intrauterine growth retardation (adjusted risk ratio 1.4), and abruptio placentae (adjusted risk ratio 9.0). A joint positive history of second-trimester elevations of maternal serum alpha-fetoprotein and placental abnormalities was more strongly associated with the following adverse infant outcomes: low birth weight (adjusted risk ratio 6.9), preterm delivery (adjusted risk ratio 5.6), and intrauterine growth retardation (adjusted risk ratio 5.3).
CONCLUSIONS: Unexplained elevated levels of maternal serum alpha-fetoprotein and placental abnormalities detected in the second trimester of pregnancy are associated with particularly poor pregnancy outcome. Careful examination for placental abnormalities should be part of the evaluation of elevated maternal serum alpha-fetoprotein.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1384333     DOI: 10.1016/s0002-9378(12)80033-0

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  12 in total

1.  The role of unexplained high serum alpha-fetoprotein (AFP) and human chorionic gonadotropin (hCG) levels in the second trimester to determine poor obstetric outcomes.

Authors:  Hümeyra Öztürk; Salim Erkaya; Sibel Altınbaş; Burak Karadağ; Nazan Vanlı Tonyalı; Demet Özkan
Journal:  Turk J Obstet Gynecol       Date:  2014-09-15

2.  Noninvasive detection of trophoblast protein signatures linked to early pregnancy loss using trophoblast retrieval and isolation from the cervix (TRIC).

Authors:  Rani Fritz; Hamid-Reza Kohan-Ghadr; Jay M Bolnick; Alan D Bolnick; Brian A Kilburn; Michael P Diamond; Sascha Drewlo; D Randall Armant
Journal:  Fertil Steril       Date:  2015-06-11       Impact factor: 7.329

3.  First-Trimester and Second-Trimester Maternal Serum Biomarkers as Predictors of Placental Abruption.

Authors:  Cande V Ananth; Ronald J Wapner; Srinidhi Ananth; Mary E DʼAlton; Anthony M Vintzileos
Journal:  Obstet Gynecol       Date:  2017-03       Impact factor: 7.661

4.  Risk of placental abruption in relation to maternal depressive, anxiety and stress symptoms.

Authors:  Nicole C de Paz; Sixto E Sanchez; Luis E Huaman; Guillermo Diez Chang; Percy N Pacora; Pedro J Garcia; Cande V Ananth; Chungfang Qiu; Michelle A Williams
Journal:  J Affect Disord       Date:  2010-08-07       Impact factor: 4.839

5.  Risk of placental abruption in relation to migraines and headaches.

Authors:  Sixto E Sanchez; Michelle A Williams; Percy N Pacora; Cande V Ananth; Chungfang Qiu; Sheena K Aurora; Tanya K Sorensen
Journal:  BMC Womens Health       Date:  2010-10-26       Impact factor: 2.809

6.  Maternal blood mitochondrial DNA copy number and placental abruption risk: results from a preliminary study.

Authors:  Michelle A Williams; Sixto E Sanchez; Cande V Ananth; Karin Hevner; Chunfang Qiu; Daniel A Enquobahrie
Journal:  Int J Mol Epidemiol Genet       Date:  2013-06-25

Review 7.  Serum screening with Down's syndrome markers to predict pre-eclampsia and small for gestational age: systematic review and meta-analysis.

Authors:  Rachel K Morris; Jeltsje S Cnossen; Marloes Langejans; Stephen C Robson; Jos Kleijnen; Gerben Ter Riet; Ben W Mol; Joris A M van der Post; Khalid S Khan
Journal:  BMC Pregnancy Childbirth       Date:  2008-08-04       Impact factor: 3.007

8.  Placental mitochondrial DNA content and placental abruption: a pilot study.

Authors:  Chunfang Qiu; Sixto E Sanchez; Karin Hevner; Daniel A Enquobahrie; Michelle A Williams
Journal:  BMC Res Notes       Date:  2015-09-16

9.  Association of high maternal blood alpha-fetoprotein level with risk of delivering small for gestational age: a meta-analysis.

Authors:  Eita Goto
Journal:  Pediatr Res       Date:  2020-09-12       Impact factor: 3.756

10.  Biochemical markers predictive of preterm delivery.

Authors:  S R Inglis
Journal:  Infect Dis Obstet Gynecol       Date:  1997
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.